{"id":"mechlorethamine","rwe":[],"_fda":{"id":"942707af-a16c-4a62-b733-103e0fac915e","set_id":"6a52e4c2-6a9f-4ebb-bc77-046b4f8bcd57","openfda":{"nui":["N0000000236","N0000175558"],"upc":["0369639120016"],"unii":["50D9XSG0VR"],"route":["TOPICAL"],"rxcui":["1437711","1437713"],"spl_id":["942707af-a16c-4a62-b733-103e0fac915e"],"brand_name":["VALCHLOR"],"spl_set_id":["6a52e4c2-6a9f-4ebb-bc77-046b4f8bcd57"],"package_ndc":["69639-120-01"],"product_ndc":["69639-120"],"generic_name":["MECHLORETHAMINE HYDROCHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["MECHLORETHAMINE"],"pharm_class_epc":["Alkylating Drug [EPC]"],"pharm_class_moa":["Alkylating Activity [MoA]"],"manufacturer_name":["Helsinn Therapeutics (U.S.), Inc."],"application_number":["NDA202317"],"is_original_packager":[true]},"version":"12","pregnancy":["8.1 Pregnancy Risk Summary Based on case reports in humans, findings in animal reproduction studies, its mechanism of action, and genotoxicity findings, mechlorethamine may cause fetal harm. Available published case reports in pregnant women receiving intravenous mechlorethamine demonstrate that mechlorethamine can cause major birth defects when a pregnant woman is systemically exposed. In animal reproduction studies, subcutaneous administration of mechlorethamine to pregnant rats and ferrets during organogenesis resulted in embryo‐fetal mortality, alterations to growth, and structural abnormalities. Based on limited available data with VALCHLOR use in pregnant women, if VALCHLOR is used during pregnancy or if the patient becomes pregnant while taking this drug, patient should be advised of the potential risk to the fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Human Data The limited available data with VALCHLOR use in pregnant women does not show evidence of congenital malformation in newborns. Cases of newborns with congenital malformations have been reported in women who received systemic mechlorethamine during pregnancy. Animal Data Mechlorethamine caused fetal malformations in the rat and ferret when given as single subcutaneous injections of 1 mg/kg. Other findings in animals included embryo lethality and growth retardation when administered as a single subcutaneous injection."],"references":["15 REFERENCES 1 OSHA Hazardous Drugs. OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html"],"description":["11 DESCRIPTION VALCHLOR is a topical product that contains mechlorethamine HCl, an alkylating drug. Mechlorethamine HCl is a white to off white solid that is very soluble in water and methanol, partially soluble in acetone, and generally not soluble in organic solvents. Mechlorethamine HCl is designated chemically as 2-chloro- N -(2-chloroethyl)- N -methylethanamine hydrochloride. The molecular weight is 192.52 and the melting point is 108-111°C. The empirical formula is C 5 H 11 Cl 2 N•HCl, and the structural formula is: CH 3 N(CH 2 CH 2 Cl) 2 •HCl. Each tube of VALCHLOR contains 60g of a gel containing 0.016% w/w of mechlorethamine (equivalent to 0.02% mechlorethamine HCl) in a base of the following inactive ingredients: diethylene glycol monoethyl ether, propylene glycol, isopropyl alcohol, glycerin, lactic acid, hydroxypropylcellulose, sodium chloride, menthol, edetate disodium, butylated hydroxytoluene."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING VALCHLOR is supplied in 60g tubes of 0.016% w/w mechlorethamine as a clear gel [NDC 69639-120-01]. Prior to dispensing, store in the freezer at -13°F to 5°F (-25°C to -15°C). Advise patients that refrigerated storage is required once dispensed. VALCHLOR is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1"],"spl_medguide":["MEDICATION GUIDE VALCHLOR ® (val-klor) (mechlorethamine) gel Important information: VALCHLOR is for use on skin only. Do not get VALCHLOR near or in your eyes, mouth, or nose. What is the most important information I should know about VALCHLOR? Keep VALCHLOR away from your eyes, mouth, and nose. If VALCHLOR gets in your eyes it can cause eye pain, burning, swelling, redness, sensitivity to light, and blurred vision. It may also cause blindness and permanent injury to your eyes. If VALCHLOR gets in your eyes, rinse your eyes right away for at least 15 minutes with a large amount of water, normal saline, or an eye wash solution. If VALCHLOR gets in your mouth or nose it can cause pain, redness, and ulcers. Rinse the affected area right away for at least 15 minutes with a large amount of water. Get medical help right away if VALCHLOR gets in your eyes, mouth, or nose. Talk with your healthcare provider before using VALCHLOR about how to get medical help. What is VALCHLOR? VALCHLOR is a prescription medicine used on the skin (topical) to treat people with Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma who have received previous skin treatment. It is not known if VALCHLOR is safe and effective in children. Do not use VALCHLOR if you are severely allergic to mechlorethamine. Tell your healthcare provider if you have had an allergic reaction to mechlorethamine. Before using VALCHLOR, tell your healthcare provider about all of your medical conditions, including if you: are pregnant or plan to become pregnant. VALCHLOR may harm your unborn baby. Avoid becoming pregnant during treatment with VALCHLOR. Tell your healthcare provider right away if you become pregnant while using VALCHLOR. -Females who are able to become pregnant should use a barrier method of birth control, such as a male condom or spermicide, during treatment with VALCHLOR. -Males with female partners who are able to become pregnant should use a barrier method of birth control, such as a male condom or spermicide, during treatment with VALCHLOR. are breastfeeding or plan to breastfeed. It is not known if VALCHLOR passes into your breast milk. Do not breastfeed during treatment with VALCHLOR. Tell your healthcare provider about all the medicines you take including prescription and over-the-counter medicines, vitamins, and herbal supplements. How should I use VALCHLOR? Use VALCHLOR exactly as your healthcare provider tells you. Caregivers must wear disposable nitrile gloves when applying VALCHLOR. Wash your hands with soap and water after touching or applying VALCHLOR. Safely throw away used disposable nitrile gloves in household trash. Apply VALCHLOR right away or within 30 minutes after you take it out of the refrigerator. Return VALCHLOR to the refrigerator right after each use. Apply a thin layer of VALCHLOR 1 time each day (or as instructed by your healthcare providers) to completely dry affected areas of the skin at least 4 hours before or 30 minutes after showering or washing. Let the treated areas dry for 5 to 10 minutes after applying VALCHLOR before covering with clothing. Moisturizers may be applied to the treated areas 2 hours before or 2 hours after applying VALCHLOR. You should not use air or water-tight bandages on areas of the skin treated with VALCHLOR. What should I avoid while using VALCHLOR? VALCHLOR is flammable. Avoid fire, flame, and smoking until VALCHLOR has dried. What are the possible side effects of VALCHLOR? See \" What is the most important information I should know about VALCHLOR?\" VALCHLOR can cause serious side effects, including: Risk of Secondary Exposure to VALCHLOR. You may have a risk of inflammation of your skin (dermatitis), injury to your eyes, mouth, or nose, and certain types of cancers. Caregivers who accidentally come into contact with VALCHLOR must wash the affected area with soap and water right away for at least 15 minutes and remove any contaminated clothing. Get medical help right away if VALCHLOR gets in your eyes, mouth, or nose. Inflammation of your skin (dermatitis) is common with VALCHLOR and may sometimes be severe. Your risk for dermatitis is increased if VALCHLOR is applied to your face, genital area, anus, or skin folds. Tell your healthcare provider if you develop skin reactions such as redness, swelling, itching, blisters, ulcers, and skin infections. Increased risk of certain types of skin cancers. Certain types of skin cancer can develop on areas of your skin that are treated with VALCHLOR and areas of your skin that are not treated with VALCHLOR. Your healthcare provider will check your skin for skin cancers during and after your treatment with VALCHLOR. Tell your healthcare provider if you get any new skin lesions. The most common side effects of VALCHLOR include: redness, swelling, itching, skin ulcers or blisters, skin infection, and darkening of areas of your skin. VALCHLOR may cause fertility problems in females and males. This could affect the ability to become pregnant. Talk to your healthcare provider if this is a concern for you. These are not all the possible side effects of VALCHLOR. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store VALCHLOR? Store VALCHLOR in the refrigerator between 36°F to 46°F (2°C to 8°C). Keep VALCHLOR away from food in the refrigerator. With clean hands, place VALCHLOR back in the box it came in and return it to the refrigerator right after each use. Talk with your pharmacist before you use VALCHLOR that has been out of the refrigerator for more than one hour a day. Safely throw away VALCHLOR that is not used after 90 days. Unused VALCHLOR, empty tubes, and used disposable nitrile gloves should be safely thrown away in household trash. Keep VALCHLOR and all medicines out of the reach of children. General information about the safe and effective use of VALCHLOR. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use VALCHLOR for a condition for which it was not prescribed. Do not give VALCHLOR to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about VALCHLOR that is written for health professionals. What are the ingredients in VALCHLOR? Active ingredient: mechlorethamine Inactive ingredients: diethylene glycol monoethyl ether, propylene glycol, isopropyl alcohol, glycerin, lactic acid, hydroxypropylcellulose, sodium chloride, menthol, edetate disodium, butylated hydroxytoluene Manufactured for: Helsinn Therapeutics (U.S.), Inc., Iselin, NJ 08830 For more information, go to www.VALCHLOR.com or call 1-855-482-5245. This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: 01/2020"],"geriatric_use":["8.5 Geriatric Use A total of 79 patients age 65 and older (31% of the clinical trial population) were treated with either VALCHLOR or the comparator in the clinical trial. Forty-four percent (44%) of patients age 65 or older treated with VALCHLOR achieved a CAILS response compared to 66% of patients below the age of 65. Seventy percent (70%) of patients age 65 and older experienced cutaneous adverse reactions and 38% discontinued treatment due to adverse reactions, compared to 58% and 14% in patients below the age of 65, respectively. Similar differences in discontinuation rates between age subgroups were observed in the comparator group."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20241120","nursing_mothers":["8.2 Lactation Risk Summary There are no data on the presence of mechlorethamine or its metabolites in human milk, the effects of the drug on the breastfed child, or the effects of the drug on milk production. Because of the potential for topical or systemic exposure to VALCHLOR through exposure to the mother's skin and the potential for serious adverse reactions in the breastfed child from mechlorethamine, advise patients not to breastfeed during treatment with VALCHLOR."],"clinical_studies":["6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In a randomized, observer-blinded, controlled trial, VALCHLOR 0.016% (equivalent to 0.02% mechlorethamine HCl) was compared to an Aquaphor ® -based mechlorethamine HCl 0.02% ointment (Comparator) [ see Clinical Studies ( 14 ) ]. The maximum duration of treatment was 12 months. Sixty-three percent (63%) of patients in the VALCHLOR arm and 67% in the comparator arm completed 12 months of treatment. The body system associated with the most frequent adverse reactions was skin and subcutaneous tissue disorders. The most common adverse reactions (occurring in at least 5% of the patients) are shown in Table 1 . Table 1. Most Commonly Reported (≥5%) Cutaneous Adverse Reactions VALCHLOR N=128 % of patients Comparator N=127 % of patients Any Grade Moderately-Severe or Severe Any Grade Moderately-Severe or Severe Dermatitis 56 23 58 17 Pruritus 20 4 16 2 Bacterial skin infection 11 2 9 2 Skin ulceration or blistering 6 3 5 2 Skin hyperpigmentation 5 0 7 0 In the clinical trial, moderately-severe to severe skin-related adverse events were managed with treatment reduction, suspension, or discontinuation. Discontinuations due to adverse reactions occurred in 22% of patients treated with VALCHLOR and 18% of patients treated with the comparator. Sixty-seven percent (67%) of the discontinuations for adverse reactions occurred within the first 90 days of treatment. Temporary treatment suspension occurred in 34% of patients treated with VALCHLOR and 20% of patients treated with the comparator. Reductions in dosing frequency occurred in 23% of patients treated with VALCHLOR and 12% of patients treated with the comparator. Reductions in hemoglobin, neutrophil count, or platelet count occurred in 13% of patients treated with VALCHLOR and 17% treated with Comparator.","14 CLINICAL STUDIES The efficacy of VALCHLOR was assessed in a randomized, multicenter, observer-blind, active-controlled, non-inferiority clinical trial of 260 patients with Stage IA, IB, and IIA mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) who had received at least one prior skin-directed therapy. Qualifying prior therapies included topical corticosteroids, phototherapy, Targretin ® gel, and topical nitrogen mustard. Patients were not required to be refractory to or intolerant of prior therapies. Patients were stratified based on Stage (IA vs. IB and IIA) and then randomized to receive VALCHLOR 0.016% (equivalent to 0.02% mechlorethamine HCl) or Aquaphor ® -based mechlorethamine HCl 0.02% ointment (Comparator) at 13 centers in the United States. Eighteen patients were excluded from the efficacy analysis due to protocol violations involving randomization at a single site. Study drug was to be applied topically on a daily basis for 12 months. Concomitant use of topical corticosteroids was not permitted during the study. Dosing could be suspended or continued with reduced frequency for dermatitis. The mean daily usage of VALCHLOR gel was 2.8 g (1 to 2 tubes per month). The maximum daily usage was 10.5 g (5 to 6 tubes per month). Patients were evaluated for a response on a monthly basis for the first 6 months and then every 2 months for the last 6 months using the Composite Assessment of Index Lesion Severity (CAILS) score. The CAILS score is obtained by adding the severity score of each of the following categories for up to 5 index lesions: erythema, scaling, plaque elevation, and surface area. Severity was graded from 0 (none) to 8 (severe) for erythema and scaling; 0 to 3 for plaque elevation; and 0 to 9 for surface area. A response was defined as greater than or equal to 50% reduction in baseline CAILS score which was confirmed at the next visit at least 4 weeks later. A complete response was defined as a confirmed CAILS score of 0. Non-inferiority was considered to have been demonstrated if the lower bound of the 95% confidence interval (CI) around the ratio of response rates (VALCHLOR/Comparator) was greater than or equal to 0.75. Patients were also evaluated using the Severity Weighted Assessment Tool (SWAT). The SWAT score is derived by measuring each involved area as a percentage of total body surface area (%BSA) and multiplying it by a severity weighting factor (1=patch, 2=plaque, 3=tumor or ulcer). A response was defined as greater than or equal to 50% reduction in baseline SWAT score which was confirmed at the next visit at least 4 weeks later. The baseline demographics and disease characteristics were balanced between treatment arms. The median age was 57 years in the VALCHLOR arm and 58 years in the comparator arm. The majority of the patients were male (60% in VALCHLOR arm, 59% in Comparator arm) and white (75% in both treatment arms). The median number of prior therapies was 2 in both treatment arms. The most common prior therapy was topical corticosteroids (used in 86% of patients in both treatment arms). The median body surface area (BSA) involvement at baseline was 8.5% (range 1%, 61%) in the VALCHLOR arm and 9% (range 1%, 76%) in the comparator arm. Sixty percent (60%) of the patients on the VALCHLOR arm and 48% of patients on the comparator arm achieved a response based on the CAILS score. VALCHLOR was non-inferior to the comparator based on a CAILS overall response rate ratio of 1.24 (95% CI 0.98, 1.58). Complete responses constituted a minority of the CAILS or SWAT overall responses ( Table 2 ). The onset of CAILS overall response for both treatment arms showed a wide range from 1 to 11 months. Table 2. Efficacy in Patients with Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL) Response Rates VALCHLOR N=119 Comparator N=123 CAILS Overall Response (CR+PR) Complete Response (CR) Partial Response (PR) 60% 14% 45% 48% 11% 37% SWAT Overall Response (CR+PR) Complete Response (CR) Partial Response (PR) 50% 7% 43% 46% 3% 43%"],"pharmacokinetics":["12.3 Pharmacokinetics Systemic exposure was undetectable after topical administration of VALCHLOR to patients. Blood samples were analyzed from 16 and 15 patients following treatment with VALCHLOR (mechlorethamine gel 0.016%) and an identical formulation consisting of mechlorethamine 0.032% w/w, respectively. For patients who received mechlorethamine 0.016%, samples were collected to measure mechlorethamine concentrations prior to dosing, on day 1, and at the first month visit. Following the topical administration of mechlorethamine 0.016%, there were no detectable plasma mechlorethamine concentrations observed in any of the patients. Patients who received mechlorethamine 0.032% had no measurable concentrations of mechlorethamine or half-mustard after 2, 4, or 6 months of treatment."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed in greater detail in other sections of the prescribing information: Mucosal or eye injury [ see Warnings and Precautions ( 5.1 ) ] Secondary exposure to VALCHLOR [ see Warnings and Precautions ( 5.2 ) ] Dermatitis [ see Warnings and Precautions ( 5.3 ) ] Non-melanoma skin cancer [ see Warnings and Precautions ( 5.4 ) ] The most common adverse reactions (≥5%) are dermatitis, pruritus, bacterial skin infection, skin ulceration or blistering, and hyperpigmentation ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Helsinn Therapeutics (U.S.), Inc., at 1-855-482-5245 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In a randomized, observer-blinded, controlled trial, VALCHLOR 0.016% (equivalent to 0.02% mechlorethamine HCl) was compared to an Aquaphor ® -based mechlorethamine HCl 0.02% ointment (Comparator) [ see Clinical Studies ( 14 ) ]. The maximum duration of treatment was 12 months. Sixty-three percent (63%) of patients in the VALCHLOR arm and 67% in the comparator arm completed 12 months of treatment. The body system associated with the most frequent adverse reactions was skin and subcutaneous tissue disorders. The most common adverse reactions (occurring in at least 5% of the patients) are shown in Table 1 . Table 1. Most Commonly Reported (≥5%) Cutaneous Adverse Reactions VALCHLOR N=128 % of patients Comparator N=127 % of patients Any Grade Moderately-Severe or Severe Any Grade Moderately-Severe or Severe Dermatitis 56 23 58 17 Pruritus 20 4 16 2 Bacterial skin infection 11 2 9 2 Skin ulceration or blistering 6 3 5 2 Skin hyperpigmentation 5 0 7 0 In the clinical trial, moderately-severe to severe skin-related adverse events were managed with treatment reduction, suspension, or discontinuation. Discontinuations due to adverse reactions occurred in 22% of patients treated with VALCHLOR and 18% of patients treated with the comparator. Sixty-seven percent (67%) of the discontinuations for adverse reactions occurred within the first 90 days of treatment. Temporary treatment suspension occurred in 34% of patients treated with VALCHLOR and 20% of patients treated with the comparator. Reductions in dosing frequency occurred in 23% of patients treated with VALCHLOR and 12% of patients treated with the comparator. Reductions in hemoglobin, neutrophil count, or platelet count occurred in 13% of patients treated with VALCHLOR and 17% treated with Comparator."],"contraindications":["4 CONTRAINDICATIONS The use of VALCHLOR is contraindicated in patients with known severe hypersensitivity to mechlorethamine. Hypersensitivity reactions, including anaphylaxis, have occurred with topical formulations of mechlorethamine. Severe hypersensitivity to mechlorethamine ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS No drug interaction studies have been performed with VALCHLOR. Systemic exposure has not been observed with topical administration of VALCHLOR; therefore, systemic drug interactions are not likely."],"spl_medguide_table":["
MEDICATION GUIDE VALCHLOR ® (val-klor) (mechlorethamine) gel
Important information: VALCHLOR is for use on skin only. Do not get VALCHLOR near or in your eyes, mouth, or nose.
What is the most important information I should know about VALCHLOR? Keep VALCHLOR away from your eyes, mouth, and nose. If VALCHLOR gets in your eyes it can cause eye pain, burning, swelling, redness, sensitivity to light, and blurred vision. It may also cause blindness and permanent injury to your eyes. If VALCHLOR gets in your eyes, rinse your eyes right away for at least 15 minutes with a large amount of water, normal saline, or an eye wash solution.If VALCHLOR gets in your mouth or nose it can cause pain, redness, and ulcers. Rinse the affected area right away for at least 15 minutes with a large amount of water.Get medical help right away if VALCHLOR gets in your eyes, mouth, or nose. Talk with your healthcare provider before using VALCHLOR about how to get medical help.
What is VALCHLOR? VALCHLOR is a prescription medicine used on the skin (topical) to treat people with Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma who have received previous skin treatment. It is not known if VALCHLOR is safe and effective in children.
Do not use VALCHLOR if you are severely allergic to mechlorethamine. Tell your healthcare provider if you have had an allergic reaction to mechlorethamine.
Before using VALCHLOR, tell your healthcare provider about all of your medical conditions, including if you:are pregnant or plan to become pregnant. VALCHLOR may harm your unborn baby. Avoid becoming pregnant during treatment with VALCHLOR. Tell your healthcare provider right away if you become pregnant while using VALCHLOR. -Females who are able to become pregnant should use a barrier method of birth control, such as a male condom or spermicide, during treatment with VALCHLOR. -Males with female partners who are able to become pregnant should use a barrier method of birth control, such as a male condom or spermicide, during treatment with VALCHLOR.are breastfeeding or plan to breastfeed. It is not known if VALCHLOR passes into your breast milk. Do not breastfeed during treatment with VALCHLOR.Tell your healthcare provider about all the medicines you take including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How should I use VALCHLOR?Use VALCHLOR exactly as your healthcare provider tells you.Caregivers must wear disposable nitrile gloves when applying VALCHLOR.Wash your hands with soap and water after touching or applying VALCHLOR.Safely throw away used disposable nitrile gloves in household trash.Apply VALCHLOR right away or within 30 minutes after you take it out of the refrigerator.Return VALCHLOR to the refrigerator right after each use.Apply a thin layer of VALCHLOR 1 time each day (or as instructed by your healthcare providers) to completely dry affected areas of the skin at least 4 hours before or 30 minutes after showering or washing.Let the treated areas dry for 5 to 10 minutes after applying VALCHLOR before covering with clothing.Moisturizers may be applied to the treated areas 2 hours before or 2 hours after applying VALCHLOR.You should not use air or water-tight bandages on areas of the skin treated with VALCHLOR.
What should I avoid while using VALCHLOR? VALCHLOR is flammable. Avoid fire, flame, and smoking until VALCHLOR has dried.
What are the possible side effects of VALCHLOR? See " What is the most important information I should know about VALCHLOR?" VALCHLOR can cause serious side effects, including: Risk of Secondary Exposure to VALCHLOR. You may have a risk of inflammation of your skin (dermatitis), injury to your eyes, mouth, or nose, and certain types of cancers. Caregivers who accidentally come into contact with VALCHLOR must wash the affected area with soap and water right away for at least 15 minutes and remove any contaminated clothing. Get medical help right away if VALCHLOR gets in your eyes, mouth, or nose.Inflammation of your skin (dermatitis) is common with VALCHLOR and may sometimes be severe. Your risk for dermatitis is increased if VALCHLOR is applied to your face, genital area, anus, or skin folds. Tell your healthcare provider if you develop skin reactions such as redness, swelling, itching, blisters, ulcers, and skin infections.Increased risk of certain types of skin cancers. Certain types of skin cancer can develop on areas of your skin that are treated with VALCHLOR and areas of your skin that are not treated with VALCHLOR. Your healthcare provider will check your skin for skin cancers during and after your treatment with VALCHLOR. Tell your healthcare provider if you get any new skin lesions.The most common side effects of VALCHLOR include: redness, swelling, itching, skin ulcers or blisters, skin infection, and darkening of areas of your skin.VALCHLOR may cause fertility problems in females and males. This could affect the ability to become pregnant. Talk to your healthcare provider if this is a concern for you.These are not all the possible side effects of VALCHLOR. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store VALCHLOR? Store VALCHLOR in the refrigerator between 36°F to 46°F (2°C to 8°C).Keep VALCHLOR away from food in the refrigerator.With clean hands, place VALCHLOR back in the box it came in and return it to the refrigerator right after each use.Talk with your pharmacist before you use VALCHLOR that has been out of the refrigerator for more than one hour a day.Safely throw away VALCHLOR that is not used after 90 days. Unused VALCHLOR, empty tubes, and used disposable nitrile gloves should be safely thrown away in household trash.Keep VALCHLOR and all medicines out of the reach of children.
General information about the safe and effective use of VALCHLOR. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use VALCHLOR for a condition for which it was not prescribed. Do not give VALCHLOR to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about VALCHLOR that is written for health professionals.
What are the ingredients in VALCHLOR? Active ingredient: mechlorethamine Inactive ingredients: diethylene glycol monoethyl ether, propylene glycol, isopropyl alcohol, glycerin, lactic acid, hydroxypropylcellulose, sodium chloride, menthol, edetate disodium, butylated hydroxytoluene Manufactured for: Helsinn Therapeutics (U.S.), Inc., Iselin, NJ 08830 For more information, go to www.VALCHLOR.com or call 1-855-482-5245.
"],"mechanism_of_action":["12.1 Mechanism of Action Mechlorethamine, also known as nitrogen mustard, is an alkylating agent which inhibits rapidly proliferating cells."],"storage_and_handling":["Prior to dispensing, store in the freezer at -13°F to 5°F (-25°C to -15°C). Advise patients that refrigerated storage is required once dispensed. VALCHLOR is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Mechlorethamine, also known as nitrogen mustard, is an alkylating agent which inhibits rapidly proliferating cells. 12.3 Pharmacokinetics Systemic exposure was undetectable after topical administration of VALCHLOR to patients. Blood samples were analyzed from 16 and 15 patients following treatment with VALCHLOR (mechlorethamine gel 0.016%) and an identical formulation consisting of mechlorethamine 0.032% w/w, respectively. For patients who received mechlorethamine 0.016%, samples were collected to measure mechlorethamine concentrations prior to dosing, on day 1, and at the first month visit. Following the topical administration of mechlorethamine 0.016%, there were no detectable plasma mechlorethamine concentrations observed in any of the patients. Patients who received mechlorethamine 0.032% had no measurable concentrations of mechlorethamine or half-mustard after 2, 4, or 6 months of treatment."],"indications_and_usage":["1 INDICATIONS AND USAGE VALCHLOR is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy. VALCHLOR is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy ( 1 )."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Mucosal or eye injury: VALCHLOR exposure to mucous membranes, especially of the eyes, can cause mucosal injury which may be severe. Eye injury may lead to blindness. Immediately irrigate for at least 15 minutes followed by immediate medical consultation ( 5.1 ). Secondary exposure to VALCHLOR: individuals other than the patient must avoid skin contact with VALCHLOR ( 2.2 , 5.2 ). Dermatitis: Monitor patients for redness, swelling, inflammation, itchiness, blisters, ulceration, and secondary skin infections. Stop treatment or reduce dose frequency ( 2.1 , 5.3 ). Non-melanoma skin cancer: Monitor patients during and after treatment ( 5.4 ). Embryo-fetal toxicity: May cause fetal harm ( 5.5 ). Flammable gel: VALCHLOR is an alcohol-based gel. Avoid fire, flame, and smoking until the gel has dried ( 2.2 , 5.6 ). 5.1 Mucosal or Eye Injury Exposure of the eyes to mechlorethamine causes pain, burns, inflammation, photophobia, and blurred vision. Blindness and severe irreversible anterior eye injury may occur. Advise patients that if eye exposure occurs, (1) immediately irrigate for at least 15 minutes with copious amounts of water, normal saline, or a balanced salt ophthalmic irrigating solution and (2) obtain immediate medical care (including ophthalmologic consultation). Exposure of mucous membranes such as the oral mucosa or nasal mucosa causes pain, redness, and ulceration, which may be severe. Should mucosal contact occur, immediately irrigate for at least 15 minutes with copious amounts of water, followed by immediate medical consultation. 5.2 Secondary Exposure to VALCHLOR Avoid direct skin contact with VALCHLOR in individuals other than the patient. Risks of secondary exposure include dermatitis, mucosal injury, and secondary cancers. Follow recommended application instructions to prevent secondary exposure [ see Dosage and Administration ( 2.2 ) ]. 5.3 Dermatitis The most common adverse reaction was dermatitis, which occurred in 56% of the patients [ see Adverse Reactions ( 6.1 ) ]. Dermatitis was moderately severe or severe in 23% of patients. Monitor patients for redness, swelling, inflammation, itchiness, blisters, ulceration, and secondary skin infections. The face, genitalia, anus, and intertriginous skin are at increased risk of dermatitis. Follow dose modification instructions for dermatitis [ see Dosage and Administration ( 2.1 ) ]. 5.4 Non-Melanoma Skin Cancer Four percent (4%, 11/255) of patients developed a non-melanoma skin cancer during the clinical trial or during one year of post-treatment follow-up: 2% (3/128) of patients receiving VALCHLOR, and 6% (8/127) of patients receiving the mechlorethamine ointment comparator. Some of these non-melanoma skin cancers occurred in patients who had received prior therapies known to cause non-melanoma skin cancer. Monitor patients for non-melanoma skin cancers during and after treatment with VALCHLOR. Non-melanoma skin cancer may occur on any area of the skin, including untreated areas. 5.5 Embryo-fetal Toxicity Based on case reports in humans, findings in animal reproduction studies, its mechanism of action, and genotoxicity findings, mechlorethamine may cause fetal harm. There are case reports of children born with malformations in pregnant women systemically administered mechlorethamine. Mechlorethamine was teratogenic and embryo-lethal after a single subcutaneous administration to animals. Advise women to avoid becoming pregnant while using VALCHLOR. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [ see Use in Specific Populations ( 8.1 ) ]. 5.6 Flammable Gel Alcohol-based products, including VALCHLOR, are flammable. Follow recommended application instructions [ see Dosage and Administration ( 2.2 ) ]."],"clinical_studies_table":["
Table 1. Most Commonly Reported (≥5%) Cutaneous Adverse Reactions
VALCHLOR N=128 % of patients Comparator N=127 % of patients
Any GradeModerately-Severe or Severe Any GradeModerately-Severe or Severe
Dermatitis56235817
Pruritus204162
Bacterial skin infection11292
Skin ulceration or blistering6352
Skin hyperpigmentation5070
","
Table 2. Efficacy in Patients with Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL)
Response RatesVALCHLOR N=119 Comparator N=123
CAILS Overall Response (CR+PR) Complete Response (CR) Partial Response (PR) 60% 14% 45% 48% 11% 37%
SWAT Overall Response (CR+PR) Complete Response (CR) Partial Response (PR) 50% 7% 43% 46% 3% 43%
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Mechlorethamine was carcinogenic in mice when injected intravenously with four doses of 2.4 mg/kg (0.1% solution) at 2-week intervals with observations for up to 2 years. An increased incidence of thymic lymphomas and pulmonary adenomas was observed. Painting mechlorethamine on the skin of mice at a dose of 4 mg/kg for periods of up to 33 weeks resulted in squamous cell tumors in 9 of 33 mice. Mechlorethamine was genotoxic in multiple genetic toxicology studies, which included mutations in the bacterial reverse mutation assay (Ames test) and chromosome aberrations in mammalian cells. Dominant lethal mutations were produced in ICR/Ha Swiss mice. The reproductive effects of VALCHLOR have not been studied; however, published literature indicates that fertility may be impaired by systemically administered mechlorethamine. Mechlorethamine impaired fertility in the male rats at a daily dose of 0.25 to 0.5 mg/kg when given intravenously every two weeks for up to 12 doses. When mechlorethamine was administered intraperitoneally to male and female mice for 4 consecutive days at a dose of 0.5 mg/kg the pregnancy rate decreased (from 80% to 12.5%) when treated males were paired with treated females. Treatment with intravenous mechlorethamine has been associated with delayed catamenia, oligomenorrhea, and temporary or permanent amenorrhea. 13.2 Animal Toxicology and/or Pharmacology Animal studies have shown mechlorethamine to be corrosive to skin and eyes, a powerful vesicant, irritating to the mucous membranes of the respiratory tract, and highly toxic by the oral route."],"adverse_reactions_table":["
Table 1. Most Commonly Reported (≥5%) Cutaneous Adverse Reactions
VALCHLOR N=128 % of patients Comparator N=127 % of patients
Any GradeModerately-Severe or Severe Any GradeModerately-Severe or Severe
Dermatitis56235817
Pruritus204162
Bacterial skin infection11292
Skin ulceration or blistering6352
Skin hyperpigmentation5070
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION See FDA-approved patient labeling ( Medication Guide ) Advise patients of the following and provide a copy of the Medication Guide. Instructions for Patients and Caregivers for Application of VALCHLOR : Apply a thin film of VALCHLOR once daily to affected areas of the skin [ see Dosage and Administration ( 2.1 ) ]. Patients must wash hands thoroughly with soap and water after handling or applying VALCHLOR. Caregivers must wear disposable nitrile gloves when applying VALCHLOR to patients and wash hands thoroughly with soap and water after removal of gloves. If there is accidental skin exposure to VALCHLOR, caregivers must immediately wash exposed areas thoroughly with soap and water and remove contaminated clothing [ see Dosage and Administration ( 2.2 ) ]. Patients and caregivers should follow these instructions when applying VALCHLOR [ see Dosage and Administration ( 2.2 ) ]: Apply immediately or within 30 minutes after removal from the refrigerator. Return VALCHLOR to the refrigerator immediately after each use. Apply VALCHLOR to completely dry skin at least 4 hours before or 30 minutes after showering or washing. Allow treated areas to dry for 5 to 10 minutes after application before covering with clothing. Emollients (moisturizers) may be applied to the treated areas 2 hours before or 2 hours after application of VALCHLOR. Occlusive (air or water-tight) dressings should not be used on areas of the skin where VALCHLOR was applied. Instructions for Patients and Caregivers for Storage of VALCHLOR Store VALCHLOR refrigerated at temperatures between 36°F - 46°F (2°C - 8°C). Advise patients that adherence to the recommended storage condition will ensure VALCHLOR will work as expected. Patients should consult a pharmacist prior to using VALCHLOR that has been left at room temperature for longer than one hour per day. Unused product should be discarded after 90 days [ see How Supplied/Storage and Handling ( 16 ) ]. With clean hands, replace tube in the original box, then place in the refrigerator. Keep VALCHLOR in its original box out of the reach of children and avoid contact with food when storing in the refrigerator. Unused VALCHLOR, empty tubes, and used application gloves should be discarded in household trash in a manner that prevents accidental application or ingestion by others, including children and pets. Mucosal or Eye Injury Exposure of the eyes to mechlorethamine causes pain, burns, inflammation, photophobia, and blurred vision. Blindness and severe irreversible eye injury may occur. Should eye contact occur, immediately irrigate for at least 15 minutes with copious amounts of water, normal saline, or a balanced salt ophthalmic irrigating solution, followed by immediate ophthalmologic consultation [ see Warnings and Precautions ( 5.1 ) ]. Exposure of mucous membranes such as the oral mucosa or nasal mucosa causes pain, redness, and ulceration, which may be severe. Should mucosal contact occur, immediately irrigate for at least 15 minutes with copious amounts of water, followed by immediate medical consultation [ see Warnings and Precautions ( 5.1 ) ]. Secondary Exposure to VALCHLOR Avoid direct skin contact with VALCHLOR in individuals other than the patient. Risks of secondary exposure include dermatitis, mucosal injury, and secondary cancers. Caregivers who help apply VALCHLOR to patients must wear disposable nitrile gloves when handling VALCHLOR. If secondary exposure occurs to eyes, mouth, or nose, immediately irrigate the exposed area for at least 15 minutes with copious amounts of water. Thoroughly wash affected areas of the skin with soap and water [ see Dosage and Administration ( 2.2 ) and Warnings and Precautions ( 5.2 ) ]. Dermatitis If patients experience skin irritation after applying VALCHLOR, such as redness, swelling, inflammation, itchiness, blisters, ulceration, or secondary skin infections, instruct patients to discuss with their physician options for changes in the treatment plan. The face, genitalia, anus, or intertriginous skin (skin folds or creases) are at increased risk of skin irritation [ see Warnings and Precautions ( 5.3 ) ]. Non-Melanoma Skin Cancers Instruct patients to notify their physician of any new skin lesions and to undergo periodic assessment for signs and symptoms of skin cancer. Non-melanoma skin cancers have been reported in patients receiving the active ingredient in VALCHLOR. Non-melanoma skin cancer may occur at multiple areas, including areas not directly treated with VALCHLOR [ see Warnings and Precautions ( 5.4 ) ]. Embryo-fetal Toxicity Advise women of the potential risk to the fetus and to avoid pregnancy while using VALCHLOR. Advise males with female partners of reproductive potential to use a barrier method of contraception while using VALCHLOR [ see Use in Specific Populations ( 8.1 , 8.3 ) ]. Lactation Advise females not to breastfeed during treatment with VALCHLOR [ see Use in Specific Populations ( 8.2 ) ]. Manufactured for: Helsinn Therapeutics, (U.S.), Inc., Iselin, NJ 08830"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION For topical dermatological use only ( 2.1 ). Apply a thin film once daily to affected areas of the skin ( 2.1 , 2.2 ). 2.1 Dosing and Dose Modification For Topical Dermatological Use Only Apply a thin film of VALCHLOR gel once daily to affected areas of the skin. Stop treatment with VALCHLOR for any grade of skin ulceration, blistering, or moderately-severe or severe dermatitis (i.e., marked skin redness with edema) [ see Warnings and Precautions ( 5.3 ) ]. Upon improvement, treatment with VALCHLOR can be restarted at a reduced frequency of once every 3 days. If reintroduction of treatment is tolerated for at least one week, the frequency of application can be increased to every other day for at least one week and then to once daily application if tolerated. 2.2 Application Instructions VALCHLOR is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 Patients must wash hands thoroughly with soap and water after handling or applying VALCHLOR. Caregivers must wear disposable nitrile gloves when applying VALCHLOR to patients and wash hands thoroughly with soap and water after removal of gloves. If there is accidental skin exposure to VALCHLOR, caregivers must immediately wash exposed areas thoroughly with soap and water for at least 15 minutes and remove contaminated clothing [ see Warnings and Precautions ( 5.2 ) ]. Patients or caregivers should follow these instructions when applying VALCHLOR: Apply immediately or within 30 minutes after removal from the refrigerator. Return VALCHLOR to the refrigerator immediately after each use. Apply to completely dry skin at least 4 hours before or 30 minutes after showering or washing. Allow treated areas to dry for 5 to 10 minutes after application before covering with clothing. Emollients (moisturizers) may be applied to the treated areas 2 hours before or 2 hours after application. Do not use occlusive dressings on areas of the skin where VALCHLOR was applied. Avoid fire, flame, and smoking until VALCHLOR has dried [ see Warnings and Precautions ( 5.6 ) ]."],"spl_product_data_elements":["VALCHLOR mechlorethamine hydrochloride DIETHYLENE GLYCOL MONOETHYL ETHER PROPYLENE GLYCOL ISOPROPYL ALCOHOL GLYCERIN LACTIC ACID, UNSPECIFIED FORM HYDROXYPROPYL CELLULOSE (1600000 WAMW) SODIUM CHLORIDE RACEMENTHOL EDETATE DISODIUM BUTYLATED HYDROXYTOLUENE MECHLORETHAMINE MECHLORETHAMINE clear"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS The active ingredient in VALCHLOR is mechlorethamine. Each tube of VALCHLOR contains 60g of 0.016% w/w mechlorethamine clear gel (equivalent to 0.02% mechlorethamine HCl). Gel: 0.016% w/w of mechlorethamine (equivalent to 0.02% mechlorethamine HCl) in 60g tubes ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed ( 8.2 ). 8.1 Pregnancy Risk Summary Based on case reports in humans, findings in animal reproduction studies, its mechanism of action, and genotoxicity findings, mechlorethamine may cause fetal harm. Available published case reports in pregnant women receiving intravenous mechlorethamine demonstrate that mechlorethamine can cause major birth defects when a pregnant woman is systemically exposed. In animal reproduction studies, subcutaneous administration of mechlorethamine to pregnant rats and ferrets during organogenesis resulted in embryo‐fetal mortality, alterations to growth, and structural abnormalities. Based on limited available data with VALCHLOR use in pregnant women, if VALCHLOR is used during pregnancy or if the patient becomes pregnant while taking this drug, patient should be advised of the potential risk to the fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Human Data The limited available data with VALCHLOR use in pregnant women does not show evidence of congenital malformation in newborns. Cases of newborns with congenital malformations have been reported in women who received systemic mechlorethamine during pregnancy. Animal Data Mechlorethamine caused fetal malformations in the rat and ferret when given as single subcutaneous injections of 1 mg/kg. Other findings in animals included embryo lethality and growth retardation when administered as a single subcutaneous injection. 8.2 Lactation Risk Summary There are no data on the presence of mechlorethamine or its metabolites in human milk, the effects of the drug on the breastfed child, or the effects of the drug on milk production. Because of the potential for topical or systemic exposure to VALCHLOR through exposure to the mother's skin and the potential for serious adverse reactions in the breastfed child from mechlorethamine, advise patients not to breastfeed during treatment with VALCHLOR. 8.3 Females and Males of Reproductive Potential Contraception Females Advise female patients of reproductive potential to use effective contraception during treatment with VALCHLOR. A barrier method of contraception should be used to avoid direct exposure of reproductive organs to VALCHLOR. Males Based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with VALCHLOR [ see Nonclinical Toxicology ( 13.1 ) ]. A barrier method of contraception should be used to avoid direct exposure of reproductive organs to VALCHLOR. Infertility Based on animal data, mechlorethamine may impair fertility in males and females [ see Nonclinical Toxicology ( 13.1 ) ]. The reversibility of the effect on fertility is unknown. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use A total of 79 patients age 65 and older (31% of the clinical trial population) were treated with either VALCHLOR or the comparator in the clinical trial. Forty-four percent (44%) of patients age 65 or older treated with VALCHLOR achieved a CAILS response compared to 66% of patients below the age of 65. Seventy percent (70%) of patients age 65 and older experienced cutaneous adverse reactions and 38% discontinued treatment due to adverse reactions, compared to 58% and 14% in patients below the age of 65, respectively. Similar differences in discontinuation rates between age subgroups were observed in the comparator group."],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology Animal studies have shown mechlorethamine to be corrosive to skin and eyes, a powerful vesicant, irritating to the mucous membranes of the respiratory tract, and highly toxic by the oral route."],"package_label_principal_display_panel":["Principal Display Panel - 60 g Tube Carton VALCHLOR ® (mechlorethamine) gel 0.016% For Topical Use Dispense with Medication Guide Before dispensing, store in freezer After dispensing, store refrigerated RX Only NET WT 60 grams NDC 69639-120-01 Carton label","Tube Label - Front Tube label front","Tube Label - Back Tube label back"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Mechlorethamine was carcinogenic in mice when injected intravenously with four doses of 2.4 mg/kg (0.1% solution) at 2-week intervals with observations for up to 2 years. An increased incidence of thymic lymphomas and pulmonary adenomas was observed. Painting mechlorethamine on the skin of mice at a dose of 4 mg/kg for periods of up to 33 weeks resulted in squamous cell tumors in 9 of 33 mice. Mechlorethamine was genotoxic in multiple genetic toxicology studies, which included mutations in the bacterial reverse mutation assay (Ames test) and chromosome aberrations in mammalian cells. Dominant lethal mutations were produced in ICR/Ha Swiss mice. The reproductive effects of VALCHLOR have not been studied; however, published literature indicates that fertility may be impaired by systemically administered mechlorethamine. Mechlorethamine impaired fertility in the male rats at a daily dose of 0.25 to 0.5 mg/kg when given intravenously every two weeks for up to 12 doses. When mechlorethamine was administered intraperitoneally to male and female mice for 4 consecutive days at a dose of 0.5 mg/kg the pregnancy rate decreased (from 80% to 12.5%) when treated males were paired with treated females. Treatment with intravenous mechlorethamine has been associated with delayed catamenia, oligomenorrhea, and temporary or permanent amenorrhea."]},"tags":[{"label":"Alkylating Drug","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L01AA05","category":"atc"},{"label":"Topical","category":"route"},{"label":"Gel","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Chronic lymphoid leukemia, disease","category":"indication"},{"label":"Chronic myeloid leukemia","category":"indication"},{"label":"Hodgkin's disease","category":"indication"},{"label":"Malignant tumor of lung","category":"indication"},{"label":"Mycosis fungoides","category":"indication"},{"label":"Non-Hodgkin's lymphoma","category":"indication"},{"label":"Recordati Rare","category":"company"},{"label":"Approved 1940s","category":"decade"},{"label":"Alkylating Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Alkylating","category":"pharmacology"},{"label":"Chemical Warfare Agents","category":"pharmacology"},{"label":"Irritants","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"},{"label":"Poisons","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"321 reports"},{"date":"","signal":"APPLICATION SITE PRURITUS","source":"FDA FAERS","actionTaken":"223 reports"},{"date":"","signal":"APPLICATION SITE ERYTHEMA","source":"FDA FAERS","actionTaken":"219 reports"},{"date":"","signal":"APPLICATION SITE PAIN","source":"FDA FAERS","actionTaken":"217 reports"},{"date":"","signal":"ERYTHEMA","source":"FDA FAERS","actionTaken":"210 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"193 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"175 reports"},{"date":"","signal":"SKIN DISCOLOURATION","source":"FDA FAERS","actionTaken":"147 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"132 reports"},{"date":"","signal":"SKIN IRRITATION","source":"FDA FAERS","actionTaken":"112 reports"}],"drugInteractions":[{"drug":"None","severity":"none","mechanism":"No systemic exposure with topical administration","management":"No specific management required","clinicalEffect":"Systemic drug interactions are not likely"}],"commonSideEffects":[{"effect":"Dermatitis","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Pruritus","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Bacterial skin infection","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Skin ulceration or blistering","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Skin hyperpigmentation","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Reductions in hemoglobin","drugRate":"13%","severity":"mild","_validated":true},{"effect":"Neutrophil count reduction","drugRate":"13%","severity":"mild","_validated":true},{"effect":"Platelet count reduction","drugRate":"13%","severity":"mild","_validated":true},{"effect":"Discontinuations due to adverse reactions","drugRate":"22%","severity":"serious","_validated":true},{"effect":"Temporary treatment suspension","drugRate":"34%","severity":"serious","_validated":true},{"effect":"Reductions in dosing frequency","drugRate":"23%","severity":"mild","_validated":true},{"effect":"Discontinuations for adverse reactions within the first 90 days","drugRate":"67%","severity":"serious","_validated":true}],"contraindications":["Acute infectious disease","Amyloidosis","Anemia","Blood coagulation disorder","Bone marrow depression","Breastfeeding (mother)","Chemotherapy-Induced Hyperuricemia","Granulocytopenic disorder","Hyperuricemia","Leukopenia","Pregnancy, function","Secondary malignant neoplasm of bone marrow","Thrombocytopenic disorder"],"specialPopulations":{"Pregnancy":"Based on case reports in humans, findings in animal reproduction studies, its mechanism of action, and genotoxicity findings, mechlorethamine may cause fetal harm. Available published case reports in pregnant women receiving intravenous mechlorethamine demonstrate that mechlorethamine can cause major birth defects when pregnant woman is systemically exposed. In animal reproduction studies, subcutaneous administration of mechlorethamine to pregnant rats and ferrets during organogenesis resulted in embryo-fetal mortality, alterations to growth, and structural abnormalities. Based on limited available data with VALCHLOR use in pregnant women, if VALCHLOR is used during pregnancy or if the patient becomes pregnant while taking this drug, patient should be advised of the potential risk to the fetus.","Geriatric use":"A total of 79 patients age 65 and older (31% of the clinical trial population) were treated with either VALCHLOR or the comparator in the clinical trial. Forty-four percent (44%) of patients age 65 or older treated with VALCHLOR achieved CAILS response compared to 66% of patients below the age of 65. Seventy percent (70%) of patients age 65 and older experienced cutaneous adverse reactions and 38% discontinued treatment due to adverse reactions, compared to 58% and 14% in patients below the age of 65.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established."}},"trials":[],"aliases":["chlormethine"],"company":"Recordati","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MECHLORETHAMINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:30:52.387043+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Mechlorethamine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:30:59.250101+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:30:57.825009+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:30:51.518199+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MECHLORETHAMINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:30:58.188621+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:30:50.498492+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:30:50.498516+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:31:17.360682+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:30:50.498521+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:30:59.666543+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:30:59.250033+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:31:10.117105+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL427/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:30:58.900065+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA202317","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:30:50.498524+00:00"}},"allNames":"valchlor","offLabel":[],"synonyms":["mustine","mechlorethamine","mustargen","nitrogen mustard","chlormethine","mechlorethamine hydrochloride","mechlorethamine HCl"],"timeline":[{"date":"1949-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from RECORDATI RARE to Recordati Rare"},{"date":"1949-03-15","type":"positive","source":"DrugCentral","milestone":"FDA approval (Recordati Rare)"},{"date":"2013-08-23","type":"positive","source":"FDA Orange Book","milestone":"Valchlor approved — EQ 0.016% BASE"}],"aiSummary":"Valchlor (Mechlorethamine) is a small molecule alkylating drug originally developed by Recordati Rare and currently owned by the same company. It was first approved by the FDA in 1949 for various cancer indications, including chronic lymphoid leukemia, Hodgkin's disease, and mycosis fungoides. As an off-patent medication, Valchlor is no longer protected by active patents, allowing for potential generic competition. Despite its age, Valchlor remains a commercial product, and its exact mechanism of action is not well understood. Key safety considerations include its potential for severe side effects and the need for careful dosing.","approvals":[{"date":"1949-03-15","orphan":false,"company":"RECORDATI RARE","regulator":"FDA"}],"brandName":"Valchlor","ecosystem":[{"indication":"Chronic lymphoid leukemia, disease","otherDrugs":[{"name":"bendamustine","slug":"bendamustine","company":"Cephalon"},{"name":"chlorambucil","slug":"chlorambucil","company":"Aspen Global Inc"},{"name":"cyclophosphamide","slug":"cyclophosphamide","company":"Baxter Hlthcare"},{"name":"duvelisib","slug":"duvelisib","company":"Verastem Inc"}],"globalPrevalence":null},{"indication":"Chronic myeloid leukemia","otherDrugs":[{"name":"cyclophosphamide","slug":"cyclophosphamide","company":"Baxter Hlthcare"},{"name":"hydroxycarbamide","slug":"hydroxycarbamide","company":"Bristol Myers Squibb"},{"name":"omacetaxine mepesuccinate","slug":"omacetaxine-mepesuccinate","company":"Ivax Intl"},{"name":"ponatinib","slug":"ponatinib","company":"Ariad"}],"globalPrevalence":480000},{"indication":"Hodgkin's disease","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"bleomycin","slug":"bleomycin","company":"Bristol Myers Squibb"},{"name":"brentuximab vedotin","slug":"brentuximab-vedotin","company":"Seattle Genetics"}],"globalPrevalence":null},{"indication":"Malignant tumor of lung","otherDrugs":[{"name":"doxorubicin","slug":"doxorubicin","company":""},{"name":"methotrexate","slug":"methotrexate","company":"Dava Pharms Inc"}],"globalPrevalence":null},{"indication":"Mycosis fungoides","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"cyclophosphamide","slug":"cyclophosphamide","company":"Baxter Hlthcare"}],"globalPrevalence":null},{"indication":"Non-Hodgkin's lymphoma","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"bleomycin","slug":"bleomycin","company":"Bristol Myers Squibb"},{"name":"carmustine","slug":"carmustine","company":"Emcure Pharms Ltd"}],"globalPrevalence":123507000},{"indication":"Pericardial Malignant Effusions","otherDrugs":[{"name":"thiotepa","slug":"thiotepa","company":""}],"globalPrevalence":null},{"indication":"Peritoneal Malignant Effusions","otherDrugs":[{"name":"thiotepa","slug":"thiotepa","company":""}],"globalPrevalence":null}],"mechanism":{"novelty":"First-in-class","moaClass":"Alkylating Activity","modality":"Small Molecule","drugClass":"Alkylating Drug [EPC]","explanation":"Mechlorethamine, also known as nitrogen mustard, is an alkylating agent which inhibits rapidly proliferating cells.","oneSentence":"Valchlor works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death.","technicalDetail":"Mechlorethamine is an alkylating agent that exerts its cytotoxic effects through the formation of cross-links in DNA, thereby inhibiting DNA replication and transcription, and ultimately leading to cell death."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Chlormethine","title":"Chlormethine","extract":"Chlormethine, also known as mechlorethamine, mustine, HN2, and embikhin (эмбихин), is a nitrogen mustard sold under the brand name Mustargen among others. It is the prototype of alkylating agents, a group of anticancer chemotherapeutic drugs. It works by binding to DNA, crosslinking two strands and preventing cell duplication. It binds to the N7 nitrogen on the DNA base guanine. As the chemical is a blister agent, its use is strongly restricted within the Chemical Weapons Convention where it is classified as a Schedule 1 substance.","wiki_history":"==History==\nThe effect of vesicant (blister) agents in the form of mustard gas (sulfur mustard, Bis(2-chloroethyl) sulfide) on bone marrow and white blood cells had been known since the First World War. In 1935 several lines of chemical and biological research yielded results that would be explored after the start of the Second World War. The vesicant action of a family of chemicals related to the sulfur mustards, but with nitrogen substituting for sulfur was discovered—the \"nitrogen mustards\" were born. The particular nitrogen mustard chlormethine (mechlorethamine) was first synthesized. And the action of sulfur mustard on tumors in laboratory animals was investigated for the first time.\n\nAfter the US entry into the Second World War the nitrogen mustards were candidate chemical warfare agents and research on them was initiated by the Office of Scientific Research and Development (OSRD). The OSRD let contracts to study them to two universities—Yale University and the University of Chicago. Inspired perhaps by the preliminary research in 1935, independently both groups thought to test whether a medically useful differential toxicity between animals and animal tumors existed. The Yale pharmacologists Louis Goodman and Alfred Gilman were the first to conduct a clinical trial, on 27 August 1942, using the agent HN3 (tris(2-chloroethyl)amine) on a patient known as J.D.\n\nThe next year the Chicago group, led by Leon O. Jacobson, conducted trials with HN2 (chlormethine) which was the only agent in this group to see eventual clinical use. Wartime secrecy prevented any of this ground-breaking work on chemotherapy from being published, but papers were released once wartime secrecy ended, in 1946."},"commercial":{"launchDate":"1949","_launchSource":"DrugCentral (FDA 1949-03-15, RECORDATI RARE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1647","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MECHLORETHAMINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MECHLORETHAMINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Chlormethine","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:06:07.457469","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:31:17.508619+00:00","fieldsConflicting":5,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"cyclophosphamide","drugSlug":"cyclophosphamide","fdaApproval":"1959-11-16","patentExpiry":"Jun 26, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"chlorambucil","drugSlug":"chlorambucil","fdaApproval":"1957-03-18","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"melphalan","drugSlug":"melphalan","fdaApproval":"1964-01-17","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ifosfamide","drugSlug":"ifosfamide","fdaApproval":"1988-12-30","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"bendamustine","drugSlug":"bendamustine","fdaApproval":"2008-03-20","patentExpiry":"Sep 26, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"melphalan flufenamide","drugSlug":"melphalan-flufenamide","fdaApproval":"2021-02-26","relationship":"same-class"}],"genericName":"mechlorethamine","indications":{"approved":[{"id":"mechlorethamine-mycosis-fungoides-type-cutaneo","name":"Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma who have received prior skin-directed therapy","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma who have received prior skin-directed therapy","diagnosticRequired":null,"brandNameForIndication":"Valchlor"}],"offLabel":[],"pipeline":[]},"currentOwner":"Recordati Rare","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"cyclophosphamide","brandName":"cyclophosphamide","genericName":"cyclophosphamide","approvalYear":"1959","relationship":"same-class"},{"drugId":"chlorambucil","brandName":"chlorambucil","genericName":"chlorambucil","approvalYear":"1957","relationship":"same-class"},{"drugId":"melphalan","brandName":"melphalan","genericName":"melphalan","approvalYear":"1964","relationship":"same-class"},{"drugId":"ifosfamide","brandName":"ifosfamide","genericName":"ifosfamide","approvalYear":"1988","relationship":"same-class"},{"drugId":"bendamustine","brandName":"bendamustine","genericName":"bendamustine","approvalYear":"2008","relationship":"same-class"},{"drugId":"melphalan-flufenamide","brandName":"melphalan flufenamide","genericName":"melphalan flufenamide","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02333162","phase":"PHASE1","title":"Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant","status":"SUSPENDED","sponsor":"University of Chicago","startDate":"2014-12-05","conditions":["Previously Treated Myelodysplastic Syndrome","Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent Adult Acute Myeloid Leukemia","Recurrent Hematologic Malignancy"],"enrollment":30,"completionDate":"2028-12-01"},{"nctId":"NCT07500220","phase":"PHASE1,PHASE2","title":"Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-03-02","conditions":["Advanced Hepatocellular Carcinoma (HCC)","Metastatic Liver Cancer"],"enrollment":30,"completionDate":"2028-03-17"},{"nctId":"NCT02567435","phase":"PHASE3","title":"Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-06-01","conditions":["Alveolar Rhabdomyosarcoma","Botryoid-Type Embryonal Rhabdomyosarcoma","Embryonal Rhabdomyosarcoma","Rhabdomyosarcoma","Sclerosing Rhabdomyosarcoma","Spindle Cell Rhabdomyosarcoma"],"enrollment":325,"completionDate":"2026-10-27"},{"nctId":"NCT00740805","phase":"PHASE1","title":"Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-08-18","conditions":["Ann Arbor Stage III Non-Hodgkin Lymphoma","Ann Arbor Stage IV Non-Hodgkin Lymphoma","Solid Neoplasm"],"enrollment":81,"completionDate":"2026-10-22"},{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":["Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type","Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type"],"enrollment":94,"completionDate":"2026-12-23"},{"nctId":"NCT01351909","phase":"PHASE1","title":"Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-05-02","conditions":["Locally Advanced Unresectable Breast Carcinoma","Metastatic Breast Carcinoma","Recurrent Breast Carcinoma","Stage IIIB Breast Cancer AJCC v7","Stage IIIC Breast Cancer AJCC v7","Stage IV Breast Cancer AJCC v6 and v7"],"enrollment":35,"completionDate":"2026-03-18"},{"nctId":"NCT04380831","phase":"EARLY_PHASE1","title":"TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-02-24","conditions":["Systemic Scleroderma"],"enrollment":15,"completionDate":"2026-12-22"},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":["Acute Myeloid Leukemia","Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm","Acute Myeloid Leukemia Post Cytotoxic Therapy","Acute Myeloid Leukemia, Myelodysplasia-Related","Myelodysplastic Syndrome"],"enrollment":2000,"completionDate":"2029-05-15"},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":["Ann Arbor Stage II Mantle Cell Lymphoma","Ann Arbor Stage III Mantle Cell Lymphoma","Ann Arbor Stage IV Mantle Cell Lymphoma"],"enrollment":16,"completionDate":"2027-09-01"},{"nctId":"NCT01856192","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-27","conditions":["Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma"],"enrollment":349,"completionDate":"2026-12-31"},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Down Syndrome"],"enrollment":6720,"completionDate":"2027-09-30"},{"nctId":"NCT07437963","phase":"PHASE1,PHASE2","title":"Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-05-01","conditions":["Recurrent Ganglioneuroblastoma","Recurrent Neuroblastoma","Refractory Ganglioneuroblastoma","Refractory Neuroblastoma"],"enrollment":76,"completionDate":"2029-09-30"},{"nctId":"NCT04088890","phase":"PHASE1","title":"Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies","status":"COMPLETED","sponsor":"Matthew Frank","startDate":"2019-09-12","conditions":["B-ALL","B-cell Non Hodgkin Lymphoma","DLBCL","Follicular Lymphoma Grade 3B"],"enrollment":52,"completionDate":"2025-03-07"},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1"],"enrollment":348,"completionDate":"2028-07-01"},{"nctId":"NCT03984448","phase":"PHASE2,PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":["Diffuse Large B-Cell Lymphoma","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Double-Expressor Lymphoma","EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present","Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":363,"completionDate":"2028-04-01"},{"nctId":"NCT07502287","phase":"PHASE1,PHASE2","title":"Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-03-02","conditions":["Relapsed Neuroblastoma","Refractory Neuroblastoma","High-Risk Neuroblastoma","Ganglioneuroblastoma"],"enrollment":36,"completionDate":"2028-06-17"},{"nctId":"NCT06058377","phase":"PHASE3","title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-27","conditions":["Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","HER2-Negative Breast Carcinoma","Hormone Receptor-Positive Breast Carcinoma"],"enrollment":3680,"completionDate":"2026-05-31"},{"nctId":"NCT06954987","phase":"PHASE2","title":"Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-17","conditions":["Acute Myeloid Leukemia"],"enrollment":244,"completionDate":"2028-05-15"},{"nctId":"NCT06904066","phase":"PHASE1","title":"Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-02","conditions":["Malignancy, Hematologic","Neoplasms, Hematologic","Neoplasms, Hematopoietic","Blood Cancer","Hematological Neoplasms","Hematopoietic Malignancies","Dysmyelopoietic Syndromes","Hematopoetic Myelodysplasia","Myeloid Leukemia, Acute","Nonlymphoblastic Leukemia, Acute","Leukemia, Lymphocytic, Acute"],"enrollment":86,"completionDate":"2029-04-30"},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":["Ganglioneuroblastoma, Nodular","Neuroblastoma"],"enrollment":478,"completionDate":"2029-12-31"},{"nctId":"NCT07223021","phase":"PHASE3","title":"A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-10-20","conditions":["B-cell Acute Lymphoblastic Leukemia"],"enrollment":130,"completionDate":"2028-10"},{"nctId":"NCT01886872","phase":"PHASE3","title":"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-01-15","conditions":["Stage I Chronic Lymphocytic Leukemia","Stage II Chronic Lymphocytic Leukemia","Stage III Chronic Lymphocytic Leukemia","Stage IV Chronic Lymphocytic Leukemia"],"enrollment":547,"completionDate":"2026-06-07"},{"nctId":"NCT05027945","phase":"PHASE2","title":"A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-23","conditions":["Immunodeficiency","Hematopoietic Stem Cell Transplantation"],"enrollment":54,"completionDate":"2026-07-01"},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":["Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8"],"enrollment":1875,"completionDate":"2031-04-28"},{"nctId":"NCT02306161","phase":"PHASE3","title":"Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-12","conditions":["Metastatic Ewing Sarcoma","Metastatic Malignant Neoplasm in the Bone","Metastatic Malignant Neoplasm in the Bone Marrow","Metastatic Malignant Neoplasm in the Lung","Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone","Peripheral Primitive Neuroectodermal Tumor of Soft Tissues"],"enrollment":312,"completionDate":"2026-09-17"},{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":["Primary Mediastinal Large B-Cell Lymphoma"],"enrollment":244,"completionDate":"2026-12-31"},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":["Acute Adult T-Cell Leukemia/Lymphoma","Adult T-Cell Leukemia/Lymphoma","Chronic Adult T-Cell Leukemia/Lymphoma","HTLV-1 Infection"],"enrollment":30,"completionDate":"2027-06-30"},{"nctId":"NCT07328503","phase":"PHASE2","title":"CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-02","conditions":["Acute Lymphoblastic Leukemia","B-All"],"enrollment":20,"completionDate":"2031-01-31"},{"nctId":"NCT02180867","phase":"PHASE2,PHASE3","title":"Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-07-11","conditions":["Alveolar Soft Part Sarcoma","Angiomatoid Fibrous Histiocytoma","Atypical Fibroxanthoma","Clear Cell Sarcoma of Soft Tissue","Epithelioid Malignant Peripheral Nerve Sheath Tumor","Epithelioid Sarcoma","Extraskeletal Myxoid Chondrosarcoma","Extraskeletal Osteosarcoma","Fibrohistiocytic Neoplasm","Fibrosarcoma","Inflammatory Myofibroblastic Tumor","Intimal Sarcoma","Leiomyosarcoma","Liposarcoma","Liver Embryonal Sarcoma","Low Grade Fibromyxoid Sarcoma","Low Grade Myofibroblastic Sarcoma","Malignant Peripheral Nerve Sheath Tumor","Malignant Skin Granular Cell Tumor","Malignant Triton Tumor","Mesenchymal Chondrosarcoma","Myxofibrosarcoma","Myxoid Chondrosarcoma","Myxoinflammatory Fibroblastic Sarcoma","Nerve Sheath Neoplasm","PEComa","Pericytic Neoplasm","Plexiform Fibrohistiocytic Tumor","Sclerosing Epithelioid Fibrosarcoma","Skin Glomus Tumor","Stage IB Soft Tissue Sarcoma AJCC v7","Stage IIB Soft Tissue Sarcoma AJCC v7","Stage III Soft Tissue Sarcoma AJCC v7","Stage IV Soft Tissue Sarcoma AJCC v7","Synovial Sarcoma","Undifferentiated High Grade Pleomorphic Sarcoma of Bone"],"enrollment":140,"completionDate":"2026-12-24"},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Adult L1 Acute Lymphoblastic Leukemia","Adult L2 Acute Lymphoblastic Leukemia","Adult T Acute Lymphoblastic Leukemia","Recurrent Adult Acute Lymphoblastic Leukemia"],"enrollment":97,"completionDate":"2027-01-06"},{"nctId":"NCT04318678","phase":"PHASE1","title":"CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2020-07-29","conditions":["AML/MDS","B-ALL","T-ALL","BPDCN"],"enrollment":108,"completionDate":"2030-07-29"},{"nctId":"NCT03623373","phase":"PHASE2","title":"Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2018-11-29","conditions":["Mantle Cell Lymphoma"],"enrollment":13,"completionDate":"2025-04-14"},{"nctId":"NCT02251821","phase":"PHASE2","title":"JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2014-10-20","conditions":["Primary Myelofibrosis","Secondary Myelofibrosis"],"enrollment":61,"completionDate":"2026-01-22"},{"nctId":"NCT02166463","phase":"PHASE3","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-03-19","conditions":["Ann Arbor Stage IIB Hodgkin Lymphoma","Ann Arbor Stage IIIB Hodgkin Lymphoma","Ann Arbor Stage IVA Hodgkin Lymphoma","Ann Arbor Stage IVB Hodgkin Lymphoma","Childhood Hodgkin Lymphoma","Classic Hodgkin Lymphoma"],"enrollment":600,"completionDate":"2026-10-03"},{"nctId":"NCT04339101","phase":"PHASE2","title":"Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-11-11","conditions":["Acute Leukemia","Hematologic and Lymphocytic Disorder","Myelodysplastic Syndrome","Primary Myelofibrosis","Secondary Myelofibrosis"],"enrollment":59,"completionDate":"2025-10-09"},{"nctId":"NCT06124157","phase":"PHASE2","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":["B Acute Lymphoblastic Leukemia"],"enrollment":222,"completionDate":"2030-12-01"},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia"],"enrollment":153,"completionDate":"2028-12-31"},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":["Grade 1 Follicular Lymphoma","Grade 2 Follicular Lymphoma","Grade 3a Follicular Lymphoma","Recurrent Follicular Lymphoma","Refractory Follicular Lymphoma"],"enrollment":73,"completionDate":"2027-01-21"},{"nctId":"NCT06413498","phase":"PHASE3","title":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2024-08-23","conditions":["Multiple Myeloma"],"enrollment":450,"completionDate":"2031-07"},{"nctId":"NCT02436707","phase":"PHASE2","title":"Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-10-27","conditions":["Lymphoma"],"enrollment":129,"completionDate":"2026-12-31"},{"nctId":"NCT07297667","phase":"PHASE1","title":"GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours","status":"NOT_YET_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2026-03-01","conditions":["Alveolar Soft Part Sarcoma","Renal Cell Carcinoma","Triple Negative Breast Cancer"],"enrollment":30,"completionDate":"2033-09-01"},{"nctId":"NCT06154252","phase":"PHASE2,PHASE3","title":"RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy","status":"RECRUITING","sponsor":"Cabaletta Bio","startDate":"2023-12-20","conditions":["Idiopathic Inflammatory Myopathy","Dermatomyositis","Anti-Synthetase Syndrome","Immune-Mediated Necrotizing Myopathy","Juvenile Dermatomyositis","Juvenile Polymyositis","Juvenile Idiopathic Inflammatory Myopathy (JIIM)","Juvenile Myositis"],"enrollment":74,"completionDate":"2028-07"},{"nctId":"NCT06733935","phase":"PHASE1,PHASE2","title":"A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)","status":"RECRUITING","sponsor":"Nkarta, Inc.","startDate":"2024-11-04","conditions":["Systemic Sclerosis","Idiopathic Inflammatory Myopathies","Antineutrophil Cytoplasmic Antibody-Associated Vasculitis"],"enrollment":144,"completionDate":"2028-10"},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":["Lymphoproliferative Disorder","HHV-8","Malignancy","HIV"],"enrollment":75,"completionDate":"2026-10-01"},{"nctId":"NCT03721068","phase":"PHASE1","title":"Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-02-19","conditions":["Neuroblastoma","Osteosarcoma"],"enrollment":18,"completionDate":"2044-06-19"},{"nctId":"NCT06834282","phase":"PHASE1","title":"CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)","status":"RECRUITING","sponsor":"CERo Therapeutics Holdings, Inc.","startDate":"2025-04-07","conditions":["AML","Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia"],"enrollment":18,"completionDate":"2029-12-31"},{"nctId":"NCT07139873","phase":"PHASE3","title":"A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)","status":"RECRUITING","sponsor":"Dizal (Jiangsu) Pharmaceutical Co., Ltd.","startDate":"2025-09-08","conditions":["Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma"],"enrollment":250,"completionDate":"2029-12"},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":["Breast Neoplasms","Triple Negative Breast Neoplasms","HR Low-Positive/HER2-Negative Breast Neoplasms"],"enrollment":2400,"completionDate":"2034-12-29"},{"nctId":"NCT05463133","phase":"PHASE1,PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-07-08","conditions":["Chronic Granulomatous Disease"],"enrollment":50,"completionDate":"2032-12-31"},{"nctId":"NCT05139017","phase":"PHASE2,PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":["DLBCL","Diffuse Large B-Cell Lymphoma"],"enrollment":290,"completionDate":"2027-09-24"},{"nctId":"NCT00428142","phase":"PHASE2","title":"Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2007-05-01","conditions":["Lymphoma"],"enrollment":95,"completionDate":"2012-01-06"},{"nctId":"NCT01176006","phase":"PHASE2","title":"Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-05","conditions":["DOCK8 Deficiency"],"enrollment":70,"completionDate":"2028-10-31"},{"nctId":"NCT02830724","phase":"PHASE1,PHASE2","title":"Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-06","conditions":["Pancreatic Cancer","Renal Cell Cancer","Breast Cancer","Melanoma","Ovarian Cancer"],"enrollment":124,"completionDate":"2028-01-01"},{"nctId":"NCT05702853","phase":"PHASE1,PHASE2","title":"Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2023-11-06","conditions":["B-cell Non Hodgkin Lymphoma","Chronic Lymphocytic Leukemia"],"enrollment":27,"completionDate":"2026-12-30"},{"nctId":"NCT07444632","phase":"PHASE1","title":"Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-08-31","conditions":["Lymphoid","Hodgkin Lymphoma"],"enrollment":60,"completionDate":"2032-09-30"},{"nctId":"NCT03328026","phase":"PHASE1,PHASE2","title":"Combination Study of SV-BR-1-GM With Retifanlimab","status":"COMPLETED","sponsor":"BriaCell Therapeutics Corporation","startDate":"2018-03-16","conditions":["Breast Cancer","Breast Neoplasm","Metastatic Breast Cancer","Breast Cancer Metastatic"],"enrollment":36,"completionDate":"2026-03-24"},{"nctId":"NCT03017820","phase":"PHASE1","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-04-04","conditions":["B-Cell Non-Hodgkin Lymphoma","Histiocytic and Dendritic Cell Neoplasm","Myelodysplastic Syndrome","Previously Treated Myelodysplastic Syndrome","Recurrent Adult Acute Myeloid Leukemia","Recurrent Anaplastic Large Cell Lymphoma","Recurrent Angioimmunoblastic T-Cell Lymphoma","Recurrent Mycosis Fungoides","Recurrent Plasma Cell Myeloma","Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Recurrent T-Cell Non-Hodgkin Lymphoma","Refractory Acute Myeloid Leukemia","Refractory Anaplastic Large Cell Lymphoma","Refractory Angioimmunoblastic T-Cell Lymphoma","Refractory Mycosis Fungoides","Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified","Refractory Plasma Cell Myeloma","Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Refractory T-Cell Non-Hodgkin Lymphoma"],"enrollment":127,"completionDate":"2032-04-01"},{"nctId":"NCT02621021","phase":"PHASE2","title":"A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-12-04","conditions":["Melanoma"],"enrollment":170,"completionDate":"2029-06-16"},{"nctId":"NCT06744504","phase":"PHASE3","title":"Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-01-10","conditions":["AML","RUNX1-RUNX1T1 Fusion Protein Expression"],"enrollment":300,"completionDate":"2029-12-01"},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":1046,"completionDate":"2032-03-29"},{"nctId":"NCT05999994","phase":"PHASE2","title":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-01-22","conditions":["Neoplasms","Child","Adolescent"],"enrollment":105,"completionDate":"2027-05"},{"nctId":"NCT06847269","phase":"PHASE2","title":"CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-05-21","conditions":["Acute Lymphoblastic Leukemia","Refractory Acute Lymphoblastic Leukemia"],"enrollment":25,"completionDate":"2031-04"},{"nctId":"NCT07493148","phase":"PHASE2","title":"Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-04-30","conditions":["Diffuse Large B-Cell Lymphoma (DLBCL)"],"enrollment":50,"completionDate":"2029-12-30"},{"nctId":"NCT07492628","phase":"PHASE1","title":"Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-03-02","conditions":["Bladder Cancer","Urothelial Carcinoma","Metastatic Urothelial Carcinoma","Locally Advanced Urothelial Carcinoma","Upper Tract Urothelial Carcinoma"],"enrollment":42,"completionDate":"2028-05-17"},{"nctId":"NCT05826535","phase":"PHASE1,PHASE2","title":"Study of LYL314 in Aggressive Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Lyell Immunopharma, Inc.","startDate":"2023-05-09","conditions":["Relapsed Non-Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma","Non-Hodgkin Lymphoma","Large B-cell Lymphoma"],"enrollment":270,"completionDate":"2031-06-30"},{"nctId":"NCT04994977","phase":"PHASE1","title":"Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2023-05-04","conditions":["Atypical Choroid Plexus Papilloma","Choroid Plexus Carcinoma"],"enrollment":1,"completionDate":"2025-12-01"},{"nctId":"NCT07493538","phase":"PHASE2","title":"MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases","status":"NOT_YET_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2026-08","conditions":["AML","MDS","Acute Leukemia","Acute Myeloid Leukemia","Myelodysplastic Syndromes"],"enrollment":132,"completionDate":"2035-03"},{"nctId":"NCT01453088","phase":"PHASE2","title":"Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2010-06-24","conditions":["Multiple Myeloma"],"enrollment":63,"completionDate":"2022-05-01"},{"nctId":"NCT07491263","phase":"PHASE1","title":"Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2026-05-01","conditions":["Relapsed/Refractory CD19-positive B-ALL"],"enrollment":6,"completionDate":"2028-12-31"},{"nctId":"NCT07015242","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-11-06","conditions":["Lymphoma"],"enrollment":65,"completionDate":"2028-12-10"},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":["Follicular Lymphoma (FL)"],"enrollment":109,"completionDate":"2031-02-20"},{"nctId":"NCT03412877","phase":"PHASE2","title":"Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-06","conditions":["Endocrine Tumors","Non-Small Cell Lung Cancer","Ovarian Cancer","Breast Cancer","Gastrointestinal/Genitourinary Cancers","Neuroendocrine Tumors","Multiple Myeloma"],"enrollment":285,"completionDate":"2028-03-23"},{"nctId":"NCT01861106","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-24","conditions":["GATA2","Immunodeficiency","MDS"],"enrollment":144,"completionDate":"2028-12-31"},{"nctId":"NCT03910452","phase":"EARLY_PHASE1","title":"Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-10-28","conditions":["Chronic Granulomatous Disease"],"enrollment":4,"completionDate":"2034-06-15"},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1","Lymphoblastic Lymphoma"],"enrollment":33,"completionDate":"2028-07-31"},{"nctId":"NCT00576979","phase":"PHASE1,PHASE2","title":"Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2008-03-04","conditions":["Leukemia"],"enrollment":51,"completionDate":"2026-01-07"},{"nctId":"NCT01808911","phase":"PHASE3","title":"Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2012-05","conditions":["Acquired Haemophilia"],"enrollment":110,"completionDate":"2021-01-14"},{"nctId":"NCT05003895","phase":"PHASE1","title":"GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-08","conditions":["Hepatocellular Carcinoma","Hepatocellular Cancer","Metastatic Hepatocellular Carcinoma"],"enrollment":38,"completionDate":"2027-12-31"},{"nctId":"NCT02133196","phase":"PHASE2","title":"T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-23","conditions":["Advanced Non-Small Cell Lung Cancer","Squamous Cell Carcinoma","Advanced NSCLC","Adenosquamous Carcinoma","Adenocarcinoma"],"enrollment":85,"completionDate":"2027-10-23"},{"nctId":"NCT06871410","phase":"PHASE1","title":"Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-02","conditions":["Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia"],"enrollment":26,"completionDate":"2028-04-01"},{"nctId":"NCT07490275","phase":"PHASE1","title":"Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":["Refractory/Relapsed Systemic Lupus Erythematosus","Refractory / Relapsed / Progressive Systemic Sclerosis","Refractory / Relapsing / Progressive Inflammatory Myopathy","Refractory / Relapsed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis","Refractory / Relapsed Connective Tissue Disease-Associated Thrombocytopenia"],"enrollment":9,"completionDate":"2028-12-31"},{"nctId":"NCT04990323","phase":"PHASE1,PHASE2","title":"US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies","status":"COMPLETED","sponsor":"ExCellThera inc.","startDate":"2021-12-01","conditions":["High Risk Myeloid Malignancies","Cord Blood Transplant"],"enrollment":13,"completionDate":"2025-12-31"},{"nctId":"NCT02654119","phase":"PHASE2","title":"Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2015-12-11","conditions":["HER2 Positive Breast Carcinoma","Stage I Breast Cancer AJCC v7","Stage IA Breast Cancer AJCC v7","Stage IB Breast Cancer AJCC v7","Stage II Breast Cancer AJCC v6 and v7","Stage IIA Breast Cancer AJCC v6 and v7","Stage IIB Breast Cancer AJCC v6 and v7"],"enrollment":20,"completionDate":"2025-12-08"},{"nctId":"NCT02298348","phase":"PHASE1","title":"Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2015-10-08","conditions":["Neuroblastoma"],"enrollment":18,"completionDate":"2026-12"},{"nctId":"NCT01479842","phase":"PHASE1","title":"Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kami Maddocks, MD","startDate":"2014-03-26","conditions":["Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Nodal Marginal Zone B-cell Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Splenic Marginal Zone Lymphoma","Waldenstrom Macroglobulinemia"],"enrollment":48,"completionDate":"2026-09-01"},{"nctId":"NCT02287311","phase":"PHASE1","title":"Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2015-02","conditions":["Hodgkin Disease","Non-Hodgkin Lymphoma","Severe Chronic Active Epstein Barr Virus","T/NK-lymphoproliferative Disease","Nasopharyngeal Carcinoma","Smooth Muscle Tumor"],"enrollment":38,"completionDate":"2029-03"},{"nctId":"NCT07214688","phase":"PHASE2","title":"Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2026-01-06","conditions":["Allogeneic Stem Cell Transplant Recipient"],"enrollment":209,"completionDate":"2032-01"},{"nctId":"NCT06528691","phase":"PHASE2","title":"Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-04","conditions":["High Grade Glioma","CNS Tumor"],"enrollment":52,"completionDate":"2032-11"},{"nctId":"NCT04799275","phase":"PHASE2,PHASE3","title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-20","conditions":["Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","Diffuse Large B-Cell Lymphoma Activated B-Cell Type","Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation","Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Grade 3b Follicular Lymphoma","HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","Intravascular Large B-Cell Lymphoma","Lymphoplasmacytic Lymphoma","Nodular Lymphocyte Predominant B-Cell Lymphoma","Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":422,"completionDate":"2027-03-01"},{"nctId":"NCT04115631","phase":"PHASE2","title":"A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-12-13","conditions":["Liver Lymphoma","Mantle Cell Lymphoma"],"enrollment":360,"completionDate":"2026-12-31"},{"nctId":"NCT06890884","phase":"PHASE2","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-11","conditions":["Lymphoma, Large B-Cell, Diffuse"],"enrollment":594,"completionDate":"2032-12-16"},{"nctId":"NCT07486089","phase":"PHASE1,PHASE2","title":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":["Breast Cancer (Locally Advanced or Metastatic)","HER2-positive Breast Cancer","Triple-Negative Breast Cancer (TNBC)"],"enrollment":60,"completionDate":"2028-03-17"},{"nctId":"NCT05436418","phase":"PHASE1,PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":["Peripheral Blood Stem Cell Transplantation","Hematopoietic Stem Cell Transplantation"],"enrollment":260,"completionDate":"2028-06-25"},{"nctId":"NCT07101432","phase":"PHASE1","title":"Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-11-04","conditions":["Head and Neck Cancer"],"enrollment":33,"completionDate":"2029-12-31"},{"nctId":"NCT00338377","phase":"PHASE2","title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-01","conditions":["Melanoma"],"enrollment":1230,"completionDate":"2030-02-28"},{"nctId":"NCT05359211","phase":"PHASE1","title":"NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-12-08","conditions":["Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent Grade 3b Follicular Lymphoma","Recurrent Primary Mediastinal Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory Grade 3b Follicular Lymphoma","Refractory Primary Mediastinal Large B-Cell Lymphoma","Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":27,"completionDate":"2026-09-04"},{"nctId":"NCT03420963","phase":"PHASE1","title":"Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-08-31","conditions":["Recurrent Cutaneous Melanoma","Recurrent Lip and Oral Cavity Carcinoma","Recurrent Malignant Endocrine Neoplasm","Recurrent Malignant Female Reproductive System Neoplasm","Recurrent Malignant Male Reproductive System Neoplasm","Recurrent Malignant Mesothelioma","Recurrent Malignant Neoplasm of Multiple Primary Sites","Recurrent Malignant Oral Neoplasm","Recurrent Malignant Pharyngeal Neoplasm","Recurrent Malignant Skin Neoplasm","Recurrent Malignant Soft Tissue Neoplasm","Recurrent Malignant Solid Neoplasm","Recurrent Malignant Thyroid Gland Neoplasm","Recurrent Malignant Urinary System Neoplasm","Refractory Cutaneous Melanoma","Refractory Malignant Bone Neoplasm","Refractory Malignant Endocrine Neoplasm","Refractory Malignant Female Reproductive System Neoplasm","Refractory Malignant Male Reproductive System Neoplasm","Refractory Malignant Mesothelioma","Refractory Malignant Neoplasm of Multiple Primary Sites","Refractory Malignant Oral Neoplasm","Refractory Malignant Pharyngeal Neoplasm","Refractory Malignant Skin Neoplasm","Refractory Malignant Soft Tissue Neoplasm","Refractory Malignant Solid Neoplasm","Refractory Malignant Thyroid Gland Neoplasm","Refractory Malignant Urinary System Neoplasm"],"enrollment":12,"completionDate":"2026-02-26"},{"nctId":"NCT07481669","phase":"PHASE2","title":"ASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":["Lymphoma Patients With High-risk of Central Nervous System Relapse"],"enrollment":45,"completionDate":"2028-03-31"},{"nctId":"NCT06375993","phase":"PHASE1","title":"A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Adicet Therapeutics","startDate":"2024-11-10","conditions":["Lupus Nephritis","Autoimmune Diseases","Systemic Sclerosis (SSc)","Systemic Lupus Erythematosus (SLE)","ANCA-Associated Vasculitis (AAV)","Idiopathic Inflammatory Myopathies","Stiff Person Syndrome"],"enrollment":180,"completionDate":"2027-12"},{"nctId":"NCT03745326","phase":"PHASE1,PHASE2","title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-16","conditions":["Gastrointestinal Cancer","Pancreatic Cancer","Gastric Cancer","Colon Cancer","Rectal Cancer"],"enrollment":5,"completionDate":"2022-08-22"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical","formulation":"Gel","formulations":[{"form":"GEL","route":"TOPICAL","productName":"VALCHLOR"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147897","MMSL":"1972","NDDF":"002630","UNII":"50D9XSG0VR","VUID":"4019808","CHEBI":"CHEBI:28925","VANDF":"4017994","INN_ID":"586","RXNORM":"155036","UMLSCUI":"C0025033","chemblId":"CHEMBL427","ChEMBL_ID":"CHEMBL427","KEGG_DRUG":"D04872","DRUGBANK_ID":"DB00888","PUBCHEM_CID":"4033","SNOMEDCT_US":"29156002","IUPHAR_LIGAND_ID":"7218","SECONDARY_CAS_RN":"55-86-7","MESH_DESCRIPTOR_UI":"D008466"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1949-","companyName":"Recordati Rare","relationship":"Original Developer"}],"publicationCount":1231,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01AA05","allCodes":["L01AA05"]},"biosimilarFilings":[],"originalDeveloper":"Recordati Rare","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Recordati Rare","companyId":"recordati","modality":"Small molecule","firstApprovalDate":"1949","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1949-03-15T00:00:00.000Z","mah":"RECORDATI RARE","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1949-03-15T00:00:00.000Z","mah":"RECORDATI RARE","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1949-03-15T00:00:00.000Z","mah":"RECORDATI RARE","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1949-03-15T00:00:00.000Z","mah":"RECORDATI RARE","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1949-03-15T00:00:00.000Z","mah":"RECORDATI RARE","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1949-03-15T00:00:00.000Z","mah":"RECORDATI RARE","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-07-09T00:00:00.000Z","mah":"HELSINN","brand_name_local":null,"application_number":"NDA202317"},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:31:17.508619+00:00","fieldsConflicting":5,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}